SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
HuMAB companies
An SI Board Since May 2000
Posts SubjectMarks Bans
1022 55 0
Emcee:  nigel bates Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
872ABLYNX ANNOUNCES INTERIM RESULTS OF FIRST NANOBODY(R) PHASE I STUDY OF ALX- 0081nigel bates-7/2/2007
871MorphoSys Announces Clinical Milestone in Partnered Therapeutic Antibody ProgramGermanecki-6/21/2007
870ABLYNX IDENTIFIES NOVEL NANOBODIES(R) ACHIEVING SECOND MILESTONE IN PROCTER &nigel bates-6/18/2007
869Thanks for posting that. <i>...Overall, there is much optimism regarding nigel bates-6/7/2007
868Antibodies: The generation game Proteomics is hungry for well-validated antibodIcebrg-6/7/2007
867Affitech Signs Antibody Research and Licensing Agreement with Roche Sunday May 6nigel bates-5/7/2007
866New Therapy For Patients With Crohn's Disease Identified Science Daily — A LJM-5/4/2007
865Bioinvent multi-100 mln eur drug sales and growing Anticoagulant market worth USB O Trust-4/23/2007
864Pharmexa and Affitech Enter into an Exclusive License Agreement to Promote Diabonigel bates-4/3/2007
863MorphoSys and Astellas Enter Antibody Partnership - Deal Seals MorphoSys's TGermanecki-3/28/2007
862Eisai Taking Over Morphotek; $325M For Antibody Foothold By Randall Osborne WeIcebrg-3/24/2007
861Symphogen and Biovitrum Initiate Phase 1 Clinical Trial with The First Recombinanigel bates-3/12/2007
860MorphoSys AG Reports Financial Results for Fiscal Year 2006 02/28/2007 at 07:30Germanecki-3/5/2007
859So much for the 'routine administrative...' <i>...in September, inigel bates-2/21/2007
858Genentech Provides Update on Cabilly Patent Reexamination Wednesday February 21,scaram(o)uche-2/21/2007
857Boehringer Ingelheim and Xencor Enter into Antibody License and Commercializationigel bates-2/13/2007
856ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials for Anticonigel bates-2/12/2007
855Up 20% in London today...nigel bates-2/9/2007
854Peptech primes itself for trade sale * Scott Murdoch * February 09, 200dr.praveen-2/9/2007
853Regeneron's Antibody Platform Draws $120M In First License By Jim Shrine StaIcebrg-2/6/2007
852Sweet deal.nigel bates-2/5/2007
851AstraZeneca Licenses Regeneron's VelocImmune(R) Technology for Discovering HIcebrg-2/5/2007
850Kirin and Astellas Enter Into Licensing Agreement on Immunosuppressive Fully Humnigel bates-1/24/2007
849Building Better Antibody Therapeutics Antibody engineering has changed a great dr.praveen-1/16/2007
8484- Antibody AG Closes CHF 17 Million Series A Financing, Bringing the Total Serinigel bates-1/15/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News